<prompt> Monoclonal antibody to IL-5 is:MepolizumbOmalizumbKeliximabAltrakincept  <response>: IL5 antagonists- reslizumab, mepolizumab, benralizumabIL5 receptor antagonist MEPOLIZUMAB: Mechanism of Action Humanized IgG1 kappa monoclonal antibody specific for IL-5; binds IL-5, and therefore stops IL-5 from binding to its receptor on the surface of eosinophils Inhibiting IL-5 binding to eosinophils reduces blood, tissue, and sputum eosinophil levels Absorption- Bioavailability: 80 Elimination Half-life: 16-22 days Systemic clearance: 0.28 Lday use:Asthma Indicated for add-on maintenance treatment of patients with severe asthma aged 12 yr, and with an eosinophilic phenotype 100 mg SC q4wk Dosing Considerations Not for the treatment of other eosinophilic conditions Not for relief of acute bronchospasm or status asthmaticus Adverse Effects- headache MOST common REF KD Tripathi 8th ed 